Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 11, 2015, Pages 2275-2285

  Hare, K M ^a   Grimwood, K ^b   Chang, A B ^a,c   Chatfield, M D ^a   Valery, P C ^a,d   Leach, A J ^a   Smith Vaughan, H C ^a,e   Morris, P S ^a,f   Byrnes, C A ^g,h   Torzillo, P J ^i,j   Cheng, A C ^k,l  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e GRIFFITH UNIVERSITY   (Australia)

^f ROYAL DARWIN HOSPITAL   (Australia)

^g UNIVERSITY OF AUCKLAND   (New Zealand)

^h Paediatric Respiratory Medicine   (New Zealand)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^k MONASH UNIVERSITY   (Australia)

^l ALFRED HEALTH   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; PENICILLIN DERIVATIVE; ANTIINFECTIVE AGENT; MACROLIDE; PLACEBO;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL LOAD; BACTERIUM CARRIER; BRONCHIECTASIS; CHILD; CONTROLLED STUDY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; INDIGENOUS AUSTRALIAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAORI (PEOPLE); MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NASOPHARYNX; PACIFIC ISLANDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; AUSTRALIA; BACTERIAL INFECTIONS; BACTERIUM; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; HETEROZYGOTE; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; NEW ZEALAND; PACIFIC ISLANDS; POPULATION GROUP; PRESCHOOL CHILD;

ANTI-BACTERIAL AGENTS; AUSTRALIA; AZITHROMYCIN; BACTERIA; BACTERIAL INFECTIONS; BRONCHIECTASIS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MACROLIDES; MALE; NASOPHARYNX; NEW ZEALAND; PACIFIC ISLANDS; PLACEBOS; POPULATION GROUPS;

EID: 84944353064     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-015-2480-0     Document Type: Article

References (43)

1. Singleton RJ, Valery PC, Morris P, Byrnes CA, Grimwood K, Redding G, Torzillo PJ, McCallum G, Chikoyak L, Mobberly C, Holman RC, Chang AB (2014) Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Pediatr Pulmonol 49(2):189–200
2. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R (2009) Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 34(4):843–849
3. Steinfort DP, Brady S, Weisinger HS, Einsiedel L (2008) Bronchiectasis in Central Australia: a young face to an old disease. Respir Med 102(4):574–578
4. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T (2012) Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 380(9842):660–667
5. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG (2013) Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 309(12):1251–1259
6. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD (2013) Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 309(12):1260–1267
7. Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, Bauert PA, Masters IB, Diaz A, McCallum GB, Mobberley C, Tjhung I, Hare KM, Ware RS, Chang AB (2013) Long-term azithromycin for indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 1(8):610–620
8. Mak DB (2006) Better late than never: a national approach to trachoma control. Med J Aust 184(10):487–488
9. Bowden FJ, Fethers K (2008) “Let’s not talk about sex”: reconsidering the public health approach to sexually transmissible infections in remote Indigenous populations in Australia. Med J Aust 188(3):182–184
10. Valery PC, Morris PS, Grimwood K, Torzillo PJ, Byrnes CA, Masters IB, Bauert PA, McCallum GB, Mobberly C, Chang AB (2012) Azithromycin for indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial. BMC Pediatr 12:122
11. DiMatteo MR (2004) Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 42(3):200–209
12. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL (2006) A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 5(3):177–185
13. Hare KM, Grimwood K, Leach AJ, Smith-Vaughan H, Torzillo PJ, Morris PS, Chang AB (2010) Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis. J Pediatr 157(6):1001–1005
14. Bell SM, Pham JN, Newton PJ, Nguyen TT (2014) Antibiotic sensitivity testing by the CDS method. A manual for medical and veterinary laboratories. Seventh edition. Available online at: http://cdstest.net/manual/
15. Bauer AW, Kirby WM, Sherris JC, Turck M (1966) Antibiotic susceptibility testing by a standardized single disk method. Tech Bull Regist Med Technol 36(3):49–52
16. Hare KM, Singleton RJ, Grimwood K, Valery PC, Cheng AC, Morris PS, Leach AJ, Smith-Vaughan HC, Chatfield M, Redding G, Reasonover AL, McCallum GB, Chikoyak L, McDonald MI, Brown N, Torzillo PJ, Chang AB (2013) Longitudinal nasopharyngeal carriage and antibiotic resistance of respiratory bacteria in indigenous Australian and Alaska native children with bronchiectasis. PLoS One 8(8):e70478
17. Leach AJ, Shelby-James TM, Mayo M, Gratten M, Laming AC, Currie BJ, Mathews JD (1997) A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 24(3):356–362
18. Morris PS, Gadil G, McCallum GB, Wilson CA, Smith-Vaughan HC, Torzillo P, Leach AJ (2010) Single-dose azithromycin versus seven days of amoxycillin in the treatment of acute otitis media in Aboriginal children (AATAAC): a double blind, randomised controlled trial. Med J Aust 192(1):24–29
19. Hare KM, Leach AJ, Morris PS, Smith-Vaughan H, Torzillo P, Bauert P, Cheng AC, McDonald MI, Brown N, Chang AB, Grimwood K (2012) Impact of recent antibiotics on nasopharyngeal carriage and lower airway infection in indigenous Australian children with non-cystic fibrosis bronchiectasis. Int J Antimicrob Agents 40(4):365–369
20. Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM, Henao-Restrepo AM, Leach AJ, Klugman KP, Porter BD, Sá-Leão R, Scott JA, Nohynek H, O’Brien KL; WHO Pneumococcal Carriage Working Group (2013) Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. Vaccine 32(1):165–179
21. Flanagan PG, Paull A (1998) Carbon dioxide requirements of Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother 42(5):669–670
22. Edwards EA, Asher MI, Byrnes CA (2003) Paediatric bronchiectasis in the twenty-first century: experience of a tertiary children’s hospital in New Zealand. J Paediatr Child Health 39(2):111–117
23. Munro KA, Reed PW, Joyce H, Perry D, Twiss J, Byrnes CA, Edwards EA (2011) Do New Zealand children with non-cystic fibrosis bronchiectasis show disease progression? Pediatr Pulmonol 46(2):131–138
24. Mills N, Best EJ, Murdoch D, Souter M, Neeff M, Anderson T, Salkeld L, Ahmad Z, Mahadevan M, Barber C, Brown C, Walker C, Walls T (2015) What is behind the ear drum? The microbiology of otitis media and the nasopharyngeal flora in children in the era of pneumococcal vaccination. J Paediatr Child Health 51(3):300–306
25. Pingault NM, Bowman JM, Lehmann D, Riley TV (2010) Antimicrobial susceptibility of Moraxella catarrhalis isolated from children in Kalgoorlie-Boulder, Western Australia. Pathology 42(3):273–279
26. Peric M, Bozdogan B, Jacobs MR, Appelbaum PC (2003) Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 47(3):1017–1022
27. Coles CL, Mabula K, Seidman JC, Levens J, Mkocha H, Munoz B, Mfinanga SG, West S (2013) Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clin Infect Dis 56(11):1519–1526
28. Haug S, Lakew T, Habtemariam G, Alemayehu W, Cevallos V, Zhou Z, House J, Ray K, Porco T, Rutar T, Keenan J, Lietman TM, Gaynor BD (2010) The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis 51(5):571–574
29. Maher MC, Alemayehu W, Lakew T, Gaynor BD, Haug S, Cevallos V, Keenan JD, Lietman TM, Porco TC (2012) The fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the field. PLoS One 7(1):e29407
30. Hansen CR, Pressler T, Hoiby N, Johansen HK (2009) Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. J Cyst Fibros 8(1):58–62
31. Phaff SJ, Tiddens HA, Verbrugh HA, Ott A (2006) Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 57(4):741–746
32. Prunier AL, Malbruny B, Laurans M, Brouard J, Duhamel JF, Leclercq R (2003) High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 187(11):1709–1716
33. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK (2007) Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 26(1):8–12
34. McCaughey G, Diamond P, Elborn JS, McKevitt M, Tunney MM (2013) Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions. PLoS One 8(7):e69763
35. Horváth A, Dobay O, Kardos S, Ghidán Á, Tóth Á, Pászti J, Ungvári E, Horváth P, Nagy K, Zissman S, Füzi M (2012) Varying fitness cost associated with resistance to fluoroquinolones governs clonal dynamic of methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 31(8):2029–2036
36. Nielsen KL, Pedersen TM, Udekwu KI, Petersen A, Skov RL, Hansen LH, Hughes D, Frimodt-Møller N (2012) Fitness cost: a bacteriological explanation for the demise of the first international methicillin-resistant Staphylococcus aureus epidemic. J Antimicrob Chemother 67(6):1325–1332
37. Tu YK, Gunnell D, Gilthorpe MS (2008) Simpson’s Paradox, Lord’s Paradox, and Suppression Effects are the same phenomenon—the reversal paradox. Emerg Themes Epidemiol 5:2
38. Assmann SF, Pocock SJ, Enos LE, Kasten LE (2000) Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355(9209):1064–1069
39. Lynch JP 3rd, Zhanel GG (2010) Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 16(3):217–225
40. Tong SY, Varrone L, Chatfield MD, Beaman M, Giffard PM (2015) Progressive increase in community-associated methicillin-resistant Staphylococcus aureus in Indigenous populations in northern Australia from 1993 to 2012. Epidemiol Infect 143:1519–1523
41. Hare KM, Stubbs E, Beissbarth J, Morris PS, Leach AJ (2010) Swab transport in Amies gel followed by frozen storage in skim milk tryptone glucose glycerol broth (STGGB) for studies of respiratory bacterial pathogens. J Microbiol Methods 81(3):253–255
42. Hare KM, Smith-Vaughan HC, Leach AJ (2011) Viability of respiratory pathogens cultured from nasopharyngeal swabs stored for up to 12 years at −70°C in skim milk tryptone glucose glycerol broth. J Microbiol Methods 86(3):364–367
43. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H (2007) Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 369(9560):482–490